Clarivate Plc
GBFinancials
Valuation Metrics
Clarivate Plc's Market Cap is $1.21B. At end of 2025 it was $2.19B. Ranked #2356 of 3,121 in US market (top 75%), #1408 of 1,658 on NYSE (top 85%), #221 of 275 in Software & Services (top 80%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.21B | US#2,356/3,121 Sec#221/275 |
| Revenue | $2.41B | US#1,337/3,121 Sec#104/275 |
| Net Income | $-334M | US—/3,121 Sec—/275 |
| Total Assets | $10.49B | US#967/3,121 Sec#59/275 |
| Net Assets | $4.54B | US#746/3,121 Sec#43/275 |
| Employees | 12,000 | US#781/3,121 Sec#57/275 |
| Value | ||
| P/B | 0.27x | US#18/3,121 Sec#1/275 |
| P/S | 0.50x | US#320/3,121 Sec#24/275 |
| EV/EBITDA | 10.94x | US#961/3,121 Sec#60/275 |
| FCF Yield | 26.97% | US#98/3,121 Sec#17/275 |
| Profitability | ||
| ROE | -7.36% | US#2,317/3,121 Sec#193/275 |
| ROA | -3.19% | US#2,455/3,121 Sec#213/275 |
| Op. Margin | -3.51% | US#2,453/3,121 Sec#216/275 |
| Revenue Growth | -3.50% | US#2,432/3,121 Sec#249/275 |
| Financial Health | ||
| Debt Ratio | 131.10% | US#1,362/3,121 Sec#126/275 |
| Total Debt | $4.26B | US#768/3,121 Sec#43/275 |
| FCF | $328M | US#1,108/3,121 Sec#105/275 |
| Cash | $218M | US#1,678/3,121 Sec#177/275 |
| Current Ratio | 0.85x | US#2,450/3,121 Sec#241/275 |
| Net Debt/EBITDA | 8.41x | US#2,314/3,121 Sec#212/275 |
| Performance | ||
| 1Y Return | -53.77% | US#2,965/3,121 Sec#253/275 |
| 1M Return | -6.86% | US#849/3,121 Sec#126/275 |
| From 52W High | -54.11% | US#2,819/3,121 Sec#229/275 |
| 1Y MDD | -58.62% | US#2,747/3,121 Sec#201/275 |
| Trading | ||
| Volume | 3,108,052 shares | US#429/3,121 Sec#51/275 |
| Trading Value | $6M | US#2,495/3,121 Sec#233/275 |
| Per Share | ||
| EPS | $-0.52 | US—/3,121 Sec—/275 |
| BPS | $7.10 | US#2,081/3,121 Sec#127/275 |
Company Info
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.